The production of mature, differentiated myeloid cells is regulated by the action of hematopoietic cytokines on progenitor cells in the bone marrow. Cytokines drive the process of myeloid differentiation by binding to specific cell-surface receptors in a stage-and lineage-specific manner. Following the binding of a cytokine to its cognate receptor, intracellular signal-transduction pathways become activated that facilitate the myeloid differentiation process. These intracellular signaling pathways may promote myelopoiesis by stimulating expansion of a progenitor pool, supporting cellular survival during the differentiation process, or by directly driving the phenotypic changes associated with differentiation. Ultimately, pathways that drive the differentiation process converge on myeloid transcription factors, including PU.1 and the C/EBP family, that are critical for differentiation to proceed. While much is known about the cytokines, cytokine receptors and transcription factors that regulate myeloid differentiation, less is known about the precise roles that specific signaling mediators play in promoting myeloid differentiation. Recently, however, the application of novel pharmacologic inhibitors, siRNA strategies, and transgenic and knockout models has begun to shed light on the involvement and function of signaling pathways in normal myeloid differentiation. This review will discuss the roles that key signaling pathways and mediators play in myeloid differentiation.
Introduction
Granulocytes and monocytes/macrophages are derived from common myeloid progenitors following induction of myeloid differentiation by hematopoietic cytokines. Mature, differentiated myeloid cells play important roles in host defense against invading microorganisms, and pathological conditions causing deficiencies in the number or function of these cells can have profound consequences. In the case of myeloid leukemias, progenitor cells are unable to undergo normal myeloid differentiation, resulting in the accumulation of proliferative blasts and reduced capacity to produce mature cells. 1 On the other end of the spectrum, the clinical administration of cytokines, such as granulocyte-colony stimulating factor (G-CSF), can be used to enhance or restore the levels of differentiated myeloid cells in patients receiving chemotherapy or radiation treatment.
The process of myeloid differentiation is regulated by the interaction of specific hematopoietic cytokines with their cognate receptors on the surface of progenitor cells present in the bone marrow. Several comprehensive reviews on the cytokines and cytokine receptors that regulate myeloid differentiation have been published. 2, 3 Following the engagement of cytokine receptors, a number of intracellular signal-transduction proteins have been reported to become activated, including Ras, Raf, MEK-1/-2 (mitogen-activated protein kinase/ERK kinase), ERK-1/-2 (extracellular signal regulated kinase), Janus family kinases (JAKs), signal transducer and activator of transcription (STATs), phosphatidylinositol 3-kinases (PI3K), Akt, protein kinase C (PKC) and Smads. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Some of these signaling proteins serve to activate myeloid transcription factors that drive the differentiation process. Excellent reviews on the expression and function of key myeloid transcription factors have been published elsewhere. [16] [17] [18] [19] However, the other roles that signaling proteins play in facilitating myeloid differentiation have only recently begun to emerge. These emerging roles include the regulation of cell cycle control proteins, apoptosis regulatory proteins and intracellular kinase signaling pathways, and will be the focus of this review.
Historically, much of what is known about the function of signaling proteins in myeloid lineage cells has been derived from studies of these proteins in leukemias. In many cases, this has created confusion regarding the role of these proteins in normal myeloid differentiation. The biological impact of activating a signaling protein in a differentiation-defective leukemic cell may be strikingly different from the effect this activation may have in normal myeloid progenitors or differentiation-competent cell lines. For example, the MEK/ERK pathway is frequently activated in differentiation-defective primary acute myeloid leukemia (AML) cells, where it is thought to contribute to enhanced proliferation and cellular survival. [20] [21] [22] [23] [24] By contrast, recent evidence indicates that activation of the MEK/ERK pathway in normal progenitors or differentiationcompetent cell lines promotes myeloid differentiation. [25] [26] [27] This review will focus on the role that specific signaling molecules play in myeloid differentiation, as derived from studies employing normal primary cells or myeloid cell line models that retain the ability to undergo differentiation. A better understanding of the pathways that mediate cytokine-induced myeloid differentiation may allow the design of novel therapeutic reagents and strategies that can be used to stimulate myelopoiesis, or potentially serve as differentiation therapies for myeloid leukemias.
JAK-STAT pathway
STAT proteins are a family of cytoplasmic transcription factors that are activated by growth factors, cytokines and hormones and participate in diverse processes such as proliferation, differentiation and survival. [28] [29] [30] [31] [32] The binding of cytokines or growth factors to their cognate receptors leads to receptor oligomerization and subsequent activation of kinase signaling by the receptor cytoplasmic domain 33 or by receptor-associated tyrosine kinases including the JAKs 34 or Src family kinases 35 (SFKs). Activation of this kinase signaling leads to direct tyrosine phosphorylation of STAT proteins followed by STAT dimerization. The homo-or hetero-dimerized STAT proteins then translocate to the nucleus where they bind to specific promoter regions and induce gene transcription. The Janus kinase family consists of four members: Tyk, JAK1, JAK2 and JAK3. JAK3 has been shown to play an important role in growth factor signaling during myeloid differentiation.
36 JAK3 expression levels were found to be low in proliferating 32Dcl3 cells (a murine myeloid progenitor cell line) grown in interleukin-3 (IL-3), but upregulated during G-CSF-induced granulocytic differentiation. In addition, induction of JAK3 phosphorylation and activation was observed during G-CSFmediated granulocytic differentiation of 32Dcl3 cells and IL-6-mediated monocytic differentiation of murine M1 cells. 37, 38 Mice that are deficient in JAK3 exhibit splenomegaly at 4 months of age and increased levels of immature neutrophils and monocytes in the peripheral blood at 5 months, indicating a vital role for JAK3 in terminal myeloid differentiation. 39 Enforced overexpression of JAK3 results in accelerated G-CSF-induced granulocytic differentiation in 32Dcl3 cells and granulocyte macrophage colony-stimulating factor (GM-CSF)-induced granulocytic and macrophage differentiation of normal mouse bone marrow cells. 37, 38 The accelerated differentiation was accompanied by cell cycle arrest, upregulation of the cyclin-dependent kinase inhibitor p27 Kip1 and downregulation of genes involved in cell cycle progression, including Cdk2, Cdk4, Cdk6 and cyclin E. The STAT protein family consists of at least seven members (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6). Of these, STAT3 and STAT5 have been shown to be important in growth factor-induced myeloid differentiation (Figure 1 ). 40, 41 STAT3 activation is induced by G-CSF and important roles for STAT3 in granulocytic differentiation have been reported in in vitro 42 and in vivo studies. 43, 44 Three distinct isoforms of STAT3, arising from a single gene, are activated by G-CSF: STAT3a, STAT3b and STAT3g. 45, 46 STAT3b is an alternatively spliced form of STAT3a with a truncated carboxyl terminus, while STAT3g represents a proteolytic fragment of STAT3a that is activated by G-CSF in differentiated neutrophils. 47 In myeloid cells capable of differentiating in response to G-CSF, STAT3b is the predominant isoform. 48 Expression of dominant-negative STAT3 (DN STAT3) mutants in murine LGM-1 and 32Dcl3 cells impairs G-CSF-induced granulocytic differentiation, but not proliferation. 42, 49, 50 STAT3 knockout mice show embryonic lethality indicating a requirement for STAT3 in early development. 51 Mice with a conditional knockout of STAT3 in macrophages and neutrophils exhibit impaired anti-inflammatory responses, and these findings have suggested an important role for STAT3 in the function of mature myeloid cells. 52 In a different study, conditional deletion of STAT3 suggested that STAT3 may not be required for neutrophilic differentiation in vivo but may be important for regulating neutrophil numbers. 53 These results are somewhat striking, as other studies have indicated an important role for STAT3 in myeloid differentiation. [40] [41] [42] [43] [44] At present, this issue remains unresolved. Yet a third study employing conditional STAT3 deletion has revealed that STAT3 plays a critical role in emergency granulopoiesis and STAT3 is also strongly induced during IL-6-induced monocytic differentiation of M1 cells, and expression of DN STAT3 blocks the monocytic differentiation of these cells. 54, 55 While the mechanism by which STAT3 promotes myeloid differentiation remains unclear, there is some evidence that STAT3 may contribute to cell cycle arrest via upregulation of the cyclindependent kinase inhibitor p27 Kip1 . 42 STAT3 may also promote differentiation by upregulating the expression and enhancing the transcriptional activity of CCAAT/enhancer binding protein alpha (C/EBPa), a key transcription factor that drives myeloid differentiation.
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STAT5 is also important in cytokine-induced myeloid differentiation. [57] [58] [59] Expression of DN STAT5 markedly inhibits G-CSF-induced neutrophilic differentiation. 58 While its precise role in the differentiation process remains to be elucidated, STAT5 may be responsible for promoting the survival of myeloid progenitors via transcriptional upregulation of the antiapoptotic protein Bcl-X L , 59 thereby allowing myeloid differentiation to proceed.
STAT1, unlike STAT3 and STAT5, is induced and activated by all-trans retinoic acid (ATRA) during myeloid differentiation of various leukemia cell lines. 60 This effect is mediated at the transcriptional level via binding of RAR/RXR heterodimers to the retinoic acid response element (RARE) in the STAT1 gene promoter.
60 STAT1 is also phosphorylated on tyrosine and serine following treatment of cells with ATRA, suggesting a role for STAT1 in ATRA-dependent signal transduction. STAT1 may contribute to ATRA-induced cell cycle arrest via regulation of cyclins, p27
Kip1 and c-Myc.
61,62

Ras signaling
Ras proteins are a family of GTPases, which serve as important signaling intermediates, relaying signals from activated receptors on the cell surface to downstream pathways. The Ras family can be subdivided based on homologies within the effector domains, with Rap, R-Ras, Ral, RheB, M-Ras, comprising one subfamily, and H-Ras, K-Ras and N-Ras comprising another. 63 Activation of Ras involves a switch from a guanosine diphosphate (GDP)-bound state to guanosine triphosphate (GTP)-bound state. Ras activation is regulated by GTPase activating proteins (GAPs) that augment the hydrolysis of GTP to GDP and by guanine nucleotide exchange factors (GEFs) that catalyze the GDP/GTP exchange. 63, 64 Activated Ras is localized to the inner surface of the plasma membrane and this localization is dependent on post-translational modifications including farnesylation of a cysteine residue near the carboxy terminus, proteolytic cleavage of the C-terminal amino acids and carboxymethylation of the farnesylated cysteine. 64 In addition, cysteine residues upstream of the farnesylated cysteine are reversibly palmitoylated. Collectively, these modifications are required for membrane affinity and biological activity of Ras. 65 The role of Ras in myeloid differentiation remains controversial. Expression of Ras has been shown to abrogate cytokine dependence in FDC-P1, 66 FDC-P2 67 and TF-1 68 cell lines. H-or N-Ras expression was also shown to inhibit hexamethylene bisacetamide-induced erythroid differentiation of D5A1 erythroleukemic cells. 69 On the other hand, mutant H-Ras was found to enhance ATRA-induced monocytic and granulocytic differentiation of human P39 myeloid cells. 70 While infection of 32Dcl3 cells with H-or K-Ras viruses failed to induce factorindependent growth, it did result in monocytic differentiation. 71 In K562 leukemic cells, expression of H-, K-or N-Ras induced growth arrest without differentiation. 72 Murine bone marrow progenitor cells infected with H-Ras virus gave rise to monocyte-macrophage colonies of highly differentiated cells, 73 while human bone marrow cells transduced with retroviruses carrying ras oncogenes showed enhanced proliferation of myeloid progenitors without characteristics of differentiation. 74 The question of whether oncogenic Ras promotes differentiation or transformation has also been addressed using mouse repopulation assays. Mice subjected to repopulation with bone marrow cells infected with activated H-ras developed T-cell or B-cell lymphomas, but no myeloid neoplasia. 75, 76 Instead enhanced monocytic/macrophage differentiation was observed. However, mice reconstituted with activated N-ras-expressing bone marrow cells developed myeloid disorders characterized by hyperproliferation of myeloid cells that retain the ability to undergo differentiation. 77 The ability of Ras to promote myeloid differentiation in certain settings may stem from its action on cell cycle progression. Ras has been shown to inhibit cell cycle progression in primary cells via mechanisms involving the p16
INK4a /Rb pathway, the p19 ARF /p53 pathway and a p53-independent/ p21 WAF1 -dependent pathway. In the p16 INK4a /Rb pathway, Ras induces the expression of INK4a and INK4b, which inhibit Cdk4 and Cdk6. 78 As a consequence of this inhibition, Rb is not phosphorylated and cells are arrested in G1. 79 A second mechanism of Ras-mediated growth arrest involves the induction of p19 ARF1 and p53. 80 Ras-induced p19 ARF1 inhibits Mdm2 activity which is required for p53 degradation by the ubiquitin/ proteosome pathway, thus resulting in the accumulation of active p53 and subsequent cell cycle arrest. [81] [82] [83] In this case, p21 WAF1 , a direct transcriptional target of p53, acts to inhibit cyclin-dependent kinases. 84, 85 A third mechanism involves cell cycle arrest via a p53-independent/p21 WAF1 -dependent pathway. 72, 86, 87 Ras-mediated growth arrest and p21 WAF1 upregulation has been demonstrated in a human leukemia cell line with a deletion in p53, p16
INK4a , p15 INK4b and p19 ARF1 . 72 The mechanisms that mediate the effects of activated Ras may prove to be cell-or tissue specific. By acting to inhibit cell cycle progression, activated Ras may render cells sensitive to the differentiation-inducing activities of hematopoietic cytokines.
Raf/MEK/ERK cascade
Raf is a serine/threonine kinase that serves as a key downstream effector of Ras. Raf proteins are activated following recruitment to the plasma membrane, interaction with Ras 88,89 and phosphorylation on specific amino acids. 90, 91 The Raf family consists of Raf-1, A-Raf and B-Raf, 92 and phosphorylation at key sites in the Raf proteins regulates their activity. In the case of Raf-1, phosphorylation of S43, S259 and S621 negatively regulates Raf activity, while phosphorylation at S338, Y340 and Y341 results in Raf activation. 88, 93, 94 Phosphorylation of S338 in Raf-1 is stimulated following Ras activation, while phosphorylation on Y340 and Y341 is mediated by SFKs. 90, 91, 94 PKC can also promote Raf activation by phosphorylating Raf-1 on S497 and S499. 95, 96 Akt mediates the phosphorylation of Raf on the negative regulatory sites S259 (Raf-1) and S364 and S428 (B-Raf). 97, 98 Antisense oligonucleotides to Raf-1 have been shown to inhibit IL-3-and GM-CSF-induced colony formation of human CD34 þ cells and murine hematopoietic progenitors. 99 Similarly, downregulation of Raf-1 protein with antisense oligonucleotides or cDNA constructs, or inhibition of Raf-1 enzymatic activity with dominant-negative mutants, was found to inhibit the proliferation of normal hematopoietic progenitors. 100 By contrast, enforced expression of activated Raf in cytokine-dependent TF-1 and FDCP-1 cells promoted cell survival and abrogated cytokine dependency, although no enhancement of myeloid differentiation was observed. 101 Evidence implicating Raf-1 in chemical-induced myeloid differentiation has also been reported. HL-60 cells undergoing monocytic differentiation in response to 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment display Raf-1 activation. 102 Moreover, a TPA-resistant variant of HL-60 cells underwent monocytic differentiation when treated with okadaic acid, which was found to activate Raf-1/mitogen-activated protein kinase (MAPK) signaling by inhibition of serine-threonine phosphatases 1 and 2A. 102 ATRA-induced granulocytic differentiation and 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL-60 cells are enhanced by overexpression of activated Raf-1 protein. 103 It has been proposed that Raf-1 signaling may be activated in two stages: early in the differentiation process where its effects are mediated through activation of the MEK/ERK cascade and later during differentiation where its effects are mediated through p90
Rsk . 104, 105 Activated Raf phosphorylates and activates the downstream kinases MEK-1 and MEK-2. 106 MEK-1 and MEK-2 are highly homologous, and are activated by phosphorylation by Raf on key serine residues (S217 and S221 of human MEK1). [107] [108] [109] The MEK-1 and MEK-2 enzymes are dual specificity kinases, which activate the serine/threonine kinases, ERK-1 and ERK-2 by phosphorylation on threonine and tyrosine residues (T202 and Y204 in ERK-1; T185 and Y187 in ERK-2). 110 Both MEKs and ERKs are activated during chemical-induced myeloid differentiation of leukemic cells. 26, 102, [111] [112] [113] In contrast to the transient activation of these enzymes in response to proliferative signals, the MEK/ERK pathway is activated in a sustained manner during ATRA-induced granulocytic differentiation and phorbol myristate acetate (PMA)-induced monocytic differentiation of HL-60 cells. 26 Inhibition of MEK-1/-2 with pharmacologic inhibitors potently inhibits myeloid differentiation, and in some cells, also inhibits differentiation-associated apoptosis. 26, 112, 113 Moreover, downregulation of MEK-1 with antisense oligonucleotides or inhibition with dominant-negative mutants was found to inhibit PMA-induced macrophage differentiation of TF-1 cells. 25 Sustained MEK/ERK activation is also observed during cytokine-induced myeloid differentiation. 27 G-CSF-induced granulocytic differentiation of 32Dcl3 has also been shown to be accompanied by a persistent MEK/ERK activation, in contrast to the transient activation seen when these cells are stimulated with IL-3, which promotes proliferation. Pharmacologic inhibition of MEK activity exerted an inhibitory effect on G-CSFmediated granulocytic differentiation of 32Dcl3, as well as IL-6-induced monocytic differentiation of M1 murine leukemic cells. 27 MEK inhibition also attenuated G-CSF-induced granulocytic differentiation of normal, bone marrow-derived CD34 þ cells. 27 G-CSF or GM-CSF potentiation of ATRA-induced differentiation of myeloid cell lines has also been shown to be mediated via the ERK-1/-2 pathway. 114 While the Raf/MEK/ERK cascade clearly plays an important role in myeloid differentiation of established cell lines and primary hematopoietic stem and progenitor cells, the mechanisms whereby this pathway impacts myeloid differentiation are incompletely understood. Several studies suggest that the MEK/ERK pathway may regulate the activation of myeloid transcription factors (Figure 2) . The serine phosphorylation Myeloid Differentiation Bcl-X L (Survival) Figure 2 Regulation of myeloid differentiation by the Raf/MEK/ERK pathway. The activation of Ras during cytokine-induced myeloid differentiation leads to phosphorylation and activation of Raf, followed by subsequent phosphorylation/activation of the MEK-1/-2 and ERK-1/-2 enzymes. Activated ERK-1/-2 acts on multiple transcription factors that regulate myeloid differentiation. ERK-1/-2 promotes serine phosphorylation of STATs, resulting in upregulation of Bcl-X L and enhancement of cell survival during the differentiation process. ERK-1/-2 also phosphorylates and enhances the DNA binding activity of PU.1 and C/EBPb, which serves to drive myeloid differentiation. In addition, ERK-1/-2 regulates the transactivation activity of AML1, another key myeloid transcription factor. By contrast, ERK-1/-2-mediated phosphorylation of S21 in C/EBPa inhibits the ability of this transcription factor to promote granulocytic differentiation.
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MB Miranda and DE Johnson status and DNA binding activity of STAT3 is attenuated following MEK-1/-2 inhibition in differentiating 32Dcl3 and M1 cells. 27 Similarly, the DNA binding of PU.1, another transcription factor that regulates hematopoietic lineage-specific differentiation, was downmodulated following inhibition of the MEK/ERK pathway. 27 Further, the expression, phosphorylation and nuclear translocation of C/EBPb, a transcription factor important for monocytic differentiation, is significantly affected by MEK/ERK inhibition. 115 On the other hand, ERK-mediated phosphorylation of C/EBPa at S21 has been reported to inhibit the ability of C/EBPa to promote granulocytic differentiation, and may also contribute to the block in differentiation in leukemias harboring FLT3 mutations. 116, 117 The MEK/ERK pathway also regulates the transactivation ability of AML1, another key myeloid transcription factor. 118 Activation of the MEK/ERK pathway also may be important for sustaining cell survival during myeloid differentiation. Upregulation of the antiapoptotic protein Bcl-X L occurs during monocytic differentiation of HL-60 cells and CD34 þ progenitor cells, an effect that is dependent on the MEK/ERK pathway. 119, 120 p38 MAPK and JNK/SAPK The p38 MAPK and JNK/SAPK (c-Jun N-terminal kinase/stressactivated protein kinase) pathways are known to mediate the effects of stress and apoptotic stimuli. [121] [122] [123] [124] The activation of upstream kinases such as MAP kinase kinase (MKK)3 and MKK6 leads to activation of p38 MAPK, while activation of MKK4 and MKK7 is required for the activation of JNK/SAPK. 123, 124 Other activators of p38 MAPK include the G proteins Cdc42 and Rac1, p21-activating kinases, and mixed lineage kinase-3.
125-127
While p38 MAPK is activated during ATRA-and arsenic trioxide-induced myeloid differentiation, it does not appear to be required for differentiation to occur. In fact, evidence suggests that inhibition of this pathway potentiates ATRAinduced granulocytic differentiation. [128] [129] [130] [131] Similarly, 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL-60 cells is enhanced by inhibitors of p38 MAPK. 132 However, p38 MAPK appears to be required for the multi-lineage differentiation of K562 cells, where inhibition of p38 MAPK signaling was found to abrogate STI571-mediated differentiation. 133 Moreover, p38 MAPK-mediated phosphorylation of C/EBPe, a transcription factor critically important for neutrophil differentiation, was shown to enhance DNA binding activity. 134 Thus, p38 MAPK has been reported to have both positive regulatory and negative regulatory effects on myeloid differentiation; further studies on the influence of cellular context on the biological impact of p38 MAPK signaling are needed. In addition, it should be noted that the growth suppressive effects of interferons and Transforming growth factor beta (TGFb) on hematopoietic progenitors have also been shown to rely on the p38 MAPK pathway. 135 There are only a few reports describing the functional role of JNK/SAPK in myeloid differentiation. The JNK/SAPK pathway is activated during TPA-induced monocytic differentiation of U937 cells, triggering the release of cytochrome c and contributing to differentiation-associated apoptosis. 136 The JNK/SAPK pathway was also shown to be important in 1,25-dihydroxyvitamin D3-induced monocytic differentiation of AML cell lines as well as M2 and M4 leukemias. 137 In addition, the JNK/SAPK pathway was found to be activated by IL-3 and G-CSF in NFS-60 and BaF3 cells but its role in the proliferative or differentiative responses of these cells has not been elucidated. 138 
Protein kinase C
The PKC family of serine/threonine kinases consists of at least 12 members which are classified as conventional PKCs (PKCa, PKCb and PKCg), novel PKCs (PKCd, PKCe, PKCZ and PKCy) and atypical PKCs (PKCz, PKCi and PKCl). 139 Most PKC isoforms have variable distributions, with PKCa, PKCd and PKCz being the most widely expressed.
In the hematopoietic system, PKC has been shown to be activated by various stimuli, including phorbol esters. TPA treatment of U937 cells results in PKC activation, cell cycle arrest, adhesion and monocytic differentiation.
140-142 U937 cells deficient in PKCb fail to undergo TPA-induced differentiation, a response that is restored upon forced expression of the PKCb enzyme. 141 Similarly, a phorbol ester-resistant mutant of HL-60 with low levels of PKCb differentiates along the monocytic lineage once PKCb expression is restored. 143 PKC is also activated following G-CSF treatment of myeloid cells, and G-CSF-induced differentiation of HL-60 cells is blocked by PKC inhibitors and calcium chelators. 144 During granulocytic differentiation of 32Dcl3 cells, PKC contributes to Ras-induced phosphorylation and activation of C/EBPa, working to drive the differentiation process. 145 ATRA treatment also leads to PKC activation. PKCd was found to be activated during ATRAinduced differentiation of NB-4 and HL-60 cells, and pharmacologic inhibition of PKCd abrogated ATRA-stimulated granulocytic differentiation. 146 Forced overexpression of a constitutively active PKCd strongly potentiated ATRA-dependent, RARE-mediated gene transcription. 146 Overexpression studies have also shown that PKCa or PKCd promote TPAinduced macrophage differentiation of 32Dcl3 cells. 147, 148 In this setting, the underlying mechanism may involve PKCmediated inhibition of IL-3-induced tyrosine phosphorylation, particularly that of Jak2. 147 In addition, overexpression of protein kinase C-z in U937 cells has been shown to induce monocytic differentiation. 149 Thus, multiple isoforms of PKC may play roles in promoting monocytic and granulocytic differentiation.
Activation of PKC has also been shown to play a role in lineage commitment of primary granulo-monocytic progenitors, with high-activity favoring macrophage differentiation and low activity leading to granulocytic differentiation. [150] [151] [152] [153] Other studies have shown that phorbol ester-induced PKC activation promotes the differentiation of HOXA9-immortalized murine bone marrow cells; PKC inhibition led to significant attenuation of differentiation in these cells. 154 Phosphorylation of HOXA9, leading to decreased DNA binding of this homeobox protein, appears to be a key step in the differentiation of these cells. 154 
Src family kinases
The SFK is comprised of nine different non-receptor tyrosine kinases: c-Src, Fyn, c-Yes, Fgr, Lyn, Hck, Lck, Blk and Yrk. 155 Most SFKs are ubiquitously expressed, although expression of Lck and Blk is largely restricted to lymphocytes 156, 157 and expression of Fgr and Hck is primarily restricted to myeloid cells. 158 The SFKs show structural similarity and consist of an SH4 domain at the N-terminus, which is myristoylated (in all SFKs) or palmitoylated (in most SFKs) for anchoring to the cell membrane. Following the SH4 domain is a unique domain of unknown function and an SH3 domain that is required for protein-protein interactions with proline-rich sequences. An SH2 domain mediates interactions with other proteins by binding to phosphotyrosine residues, while an SH2-kinase linker domain contains Tyr416, which is a substrate for autophosphorylation and is important for kinase activity. Additionally, SFKs contain an SH1 catalytic domain and a C-terminal negative regulatory domain containing Tyr530, the phosphorylation of which is brought about by C-terminal Src kinase and results in inactivation of SFKs. 159, 160 SFK activation is regulated by phosphorylation. In the case of c-Src, the inactive conformation is maintained by intramolecular interaction of the SH2 domain with the C-terminal phosphorylated Tyr530 and interaction of the SH3 domain with the SH2-kinase linker region, keeping Tyr416 in a dephosphorylated form. Activation of c-Src requires dephosphorylation of Tyr530 and phosphorylation of Tyr416 within the activation loop, resulting in a catalytically active conformation. 161, 162 SFKs have been implicated in diverse processes such as proliferation, survival, differentiation, cytoskeletal reorganization, vesicle trafficking, adhesion and migration. The activation of SFKs is induced by activated receptor tyrosine kinases (RTKs) 163 or G-protein-coupled receptors (GPCR). 164 Activation by RTKs may occur by direct association of the SFK with the RTK, or may be more complex involving Ras and Ral GTPases 165 and Shp2 phosphatase. 166 Activation of SFKs by GPCRs can occur by direct interaction of the SFK with the GPCR intracellular domain, 167 by binding to GPCR-activated G protein subunits, 168 or via crosstalk between GPCRs and RTKs. 169, 170 Once activated, SFKs phosphorylate a number of targets, and this serves to integrate SFKs with other signaling pathways that regulate myeloid differentiation. In growth factor stimulated cells, SFKs can mediate tyrosine phosphorylation of STAT proteins. [171] [172] [173] [174] SFKs also activate the Ras/Raf/MEK/ERK pathway via recruitment of Shc and Shp2 proteins, which in turn interact with the adapter protein Grb2 and the GEF Sos leading to the activation of Ras and its downstream effectors, Raf/MEK/ ERK. 175, 176 In addition, Ras can be activated in the Golgi apparatus by an SFK-dependent mechanism. 177 SFKs have also been implicated in integrin signaling and have been shown to phosphorylate focal adhesion kinase, p130CAS, p190RhoGAP and paxillin. 178 PKCd is phosphorylated on several tyrosine residues by SFKs, including Tyr311, which target the phosphorylated protein for proteosomal degradation. 179, 180 Activation of the PI3K/Akt pathway can be mediated by SFKs via either direct interaction with Yes and Lyn in a growth factor receptor complex, 181, 182 or indirectly via SFK-mediated phosphorylation of the adaptor protein Cbl. 183 SFKs can also modulate the activity of RTKs. SFKs have been shown to phosphorylate activated EGFR, PDGFR, SCFR and IGF-1R tyrosine kinases on tyrosine residues that are distinct from those that are rapidly phosphorylated upon growth factor stimulation. [184] [185] [186] [187] SFKmediated phosphorylation at these sites positively regulates the activation of RTKs and the impact of the RTKs on DNA synthesis and cell adhesion. Further, SFKs regulate the endocytosis of RTKs by phosphorylating clathrin and dynamin. 188, 189 An important role of SFKs during myeloid differentiation is to promote cell survival during the differentiation process. The expression and activation of Lyn and Fgr have been found to be induced during ATRA-induced granulocytic differentiation of HL-60 cells. 190 Treatment with antisense oligonucleotides against lyn or fgr mRNA resulted in premature death of the differentiating cells. 190 Similarly, high levels of c-Src kinase expression and activity were seen in HL-60 and U937 cells undergoing PMA-induced monocytic differentiation. 191 Elevated expression of Fgr and Hck were also observed in AML leukemic blasts that were induced to differentiate along the monocytic or granulocytic lineages. 158 SFKs also regulate the proliferation and survival of myeloid progenitors. Lyn was shown to be associated with c-kit and activated upon stem cell factor (SCF) stimulation of hematopoietic cell lines and normal progenitors. 192, 193 Inhibition of Lyn activity potently inhibited SCF-induced proliferation of these cells. Expression of v-Src in 32Dcl3 cells abrogated IL-3 dependence and promoted IL-3-independent growth and survival. 194 Similarly, retroviral expression of Hck in 32Dcl3 cells prolonged the survival of these cells upon IL-3 withdrawal. 195 Lyn-deficient DT40 cells expressing G-CSF receptor showed impaired responsiveness to G-CSF, manifested by reduced phosphorylation of Cbl, Shc, Gab2 and PI3K, and reduced DNA synthesis compared to wild-type cells. 196, 197 Ectopic expression of Lyn restored the G-CSF-dependent proliferative responses of these cells. 198 The promotion of cell survival by SFKs is probably brought about by the activation of downstream signaling molecules such as PI3K/Akt and STATs which are known to phosphorylate and inactivate proapoptotic Bad protein and increase the expression of antiapoptotic Bcl-X L protein, respectively. 199, 200 Insight into the roles of SFKs in myeloid development has been gained through the study of knockout models (Figure 3) . Lyn À/À mice are marked by increased myeloid progenitors in the bone marrow and are prone to develop monocyte/macrophage tumors. 201 Another study showed that lyn À/À mice manifest an increase in granulocytic progenitors, granulocyte-monocytic progenitors and multipotential progenitors, implicating Lyn in the negative regulation of myeloid progenitor pool expansion and survival. 202 Myeloid progenitors derived from Hck-deficient mice exhibited increased proliferation in response to G-CSF stimulation, indicating an inhibitory role for Hck in G-CSFinduced proliferation of granulocytic precursors. Lyn, Fgr and Hck single knockout mice display normal granulocytic differentiation but defective adhesion-dependent neutrophil functions. 203, 204 c-Src knockout mice do not show impaired myelopoesis, but develop severe osteoporosis. 205 The subtlety of the myeloid defects seen in single knockouts may be explained by redundant functions among the different SFKs.
Double knockouts of SFKs have more apparent effects on myeloid development. Integrin signaling abnormalities in the 
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MB Miranda and DE Johnson bone marrow environment leading to defective adhesiondependent neutrophil functions are seen in hck À/À fgr À/À double mutant mice. 203, 206 Most hck À/À src À/À double knockout mice die at birth, while those that survive develop severe splenic extramedullary hematopoiesis, anemia, leucopenia and osteoporosis. By contrast, fgr À/À src À/À mice show no defects other than the osteoporosis typical of src À/À mice. 204 Mice deficient in both Hck and Fgr develop an immunodeficiency which predisposes them to Listeria infections. 207 Src À/À fyn À/À and src À/À yes À/À double mutants die at birth, while fyn À/À yes À/À mice, although viable, suffer from degenerative renal disease. 208 Triple knockout (hck À/À lyn À/À fgr À/À ) mice (HLF mice) are remarkable for being relatively healthy with normal responses to lipopolysaccharide stimulation and normal phagocytic functions. 209, 210 However, HLF mice manifest enhanced neutrophil responses to G-CSF. 202 In addition, HLF mice have increased levels of bone marrow progenitors and show a hyperproliferative response to G-CSF in vitro. Altogether, studies with knockout mice indicate that SFKs play an inhibitory role in progenitor pool expansion and neutrophil production, but a positive and sometimes redundant role in maintaining the function of differentiated myeloid cells.
PI3K-Akt pathway
PI3K are lipid kinases that phosphorylate phosphatidylinositol and phosphoinositides, leading to the activation of downstream signaling pathways that are important in cellular metabolism and survival. 211 PI3Ks are classified into three groups (classes I, II or III) based on their sequence homology and substrate specificity. Class I PI3Ks can be further subdivided into class IA PI3Ks that are activated by growth factor RTKs as well as by GPCR, and class IB PI3Ks that are activated only by GPCR. Class IA PI3Ks consist of a p85 regulatory subunit and a p110 catalytic subunit, with each subunit having several isoforms, while class IB PI3Ks possess only the p110 catalytic subunit. 212 Class II PI3Ks consist of a single p110 catalytic unit, participate in membrane trafficking, and can be activated by RTKs, cytokines and integrins. 213 Class III PI3Ks include VPS 34 (vacuolar protein sorting defective 34) which plays a role in cell growth and autophagy. 214, 215 Class I PI3Ks are important in hematopoietic cell signaling, and likely contribute to myeloid differentiation primarily by sustaining cell survival (Figure 4 ). The activation of cytokine receptors, Ras, SFKs (Lyn, Fyn, Lck or c-Src) or adapter proteins (Grb2, Shc, Cbl) leads to the recruitment of PI3K to the plasma membrane and its subsequent activation. [216] [217] [218] Activated PI3Ks produce phosphoinositide-3-phosphate and phosphoinositide-3, 4, 5-triphosphate which are required for the activation of phosphoinositide-dependent kinases (PDK1 and PDK2). 219 The PDKs, in turn, activate Akt, also known as protein kinase B, by phosphorylating Akt on key serine and threonine residues. 220 The known biological functions of Akt include the regulation of glucose transport and promotion of cell survival. Akt exerts its antiapoptotic effects via phosphorylation of several proteins involved in apoptosis regulation. One such target is the proapoptotic protein Bad, which upon phosphorylation by Akt becomes sequestered by 14-3-3 protein. This prevents Bad from interacting with, and inhibiting the antiapoptotic proteins Bcl-2 and Bcl-X L . 221 Akt also phosphorylates and inactivates caspase-9, as well as the forkhead transcription factors known to activate Fas ligand (FasL) transcription. 222, 223 Other targets of Akt include IKK (inhibitor of nuclear factor-kB kinase), MDM2 and GSK-3 (glycogen synthease kinase-3), which facilitate cell survival and cell cycle progression. [224] [225] [226] [227] The PI3K/Akt pathway is activated by G-CSF in BaF3 and 32Dcl3 cells via a pathway involving SFK. 228 The PI3K/Akt pathway can also be activated by MEK. Expression of conditionally active MEK1 in TF-1, FDC-P1 and FL5.12 cells led to activation of the PI3K/Akt/p70S6K pathway and coexpression of activated MEK and PI3K or Akt resulted in cytokine independence and resistance to apoptosis. [229] [230] [231] The mTOR/ p70S6 kinase pathway is activated during ATRA-induced differentiation of NB-4 cells and this activation is mediated via PI3K. 232 Activation of the PI3K/Akt pathway was also observed during 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL-60 cells. 233 Inhibition of the Akt pathway with pharmacologic inhibitors enhanced vitamin D3-induced cell cycle arrest, increased the expression of p27 Kip1 and promoted apoptosis in HL-60 cells. 233 Inactivation of PTEN (phosphatase and tensin homologue), a negative regulator of the PI3K/Akt pathway, results in expansion of bone marrow hematopoietic stem cells. 234 Moreover, mice with a mutant PTEN develop conditions reminiscent of AML or lymphoid leukemia. 234 
TGFb/SMAD signaling pathway
TGFb is a potent negative regulator of hematopoiesis. 235 TGFb has several isoforms (TGFb1-TGFb5), [236] [237] [238] and binding of TGFb to its receptor (I, II or III) [239] [240] [241] activates the receptor serine/threonine kinase, which in turn activates several intracellular signaling pathways. The Smad protein family (Smad1-8) acts as mediators of TGFb signaling. 242 Smad1, 2, 3, 5 and 8 are phosphorylated by TGFb-activated receptor kinases and form complexes with the co-mediator Smad4. These activated Smad complexes translocate to the nucleus where they activate transcription. [243] [244] [245] [246] [247] However, not all Smad proteins serve as positive mediators of TGFb signaling. Smad6 and Smad7 inhibit TGFb signaling by competing with the receptor-activated Smads TGFb1 regulates hematopoiesis at various levels ranging from its effects on hematopoietic stem cells to effects on granulocytemonocyte progenitors. In the case of hematopoietic stem cells, TGFb1 exerts a growth inhibitory effect. Treatment with TGFb1 blocking antibodies or TGFb1 antisense oligonucleotides releases the stem cells from their quiescent state to an active cycling state allowing subsequent expansion of this population to occur. 251 The differentiation of myeloid progenitors into granulocyte or monocytes, on the other hand, is enhanced by TGFb. [252] [253] [254] Several studies have demonstrated that the negative regulation of hematopoiesis by TGFb is mediated by the Smad proteins. Treatment of CD34 þ cells with Smad5 antisense oligonucleotides was found to reverse TGFb inhibition of myeloid, erythroid, megakaryocyte and multilineage colony formation. 255 Smad5 also plays a role in inhibiting the selfrenewal ability of primitive progenitors in embryonic hematopoiesis, but not adult hematopoiesis. 256 In a different study, bone morphogenetic proteins (BMPs), members of the TGFb superfamily, were shown to regulate the proliferation and differentiation of primitive hematopoietic cells, with low doses inducing proliferation and differentiation of the primitive CD34 þ CD38 À lin À cells, while higher doses inhibited the proliferation of these cells and maintained their phenotype. These effects were believed to be mediated by the Smad proteins whose expression in the primitive hematopoietic cells was induced in a dose-dependent manner by BMPs. 257 Overexpression of Smad7 in primitive hematopoietic progenitor cells leads to enhanced myeloid engraftment in non-obese diabetic-severe combined immunodeficient (NOD/SCID) recipient mice. 258 Moreover, overexpression of Smad7 in hematopoietic stem cells increased the self-renewal capacity of the stem cells in vivo while maintaining their differentiation ability. 259 TGFb also exerts effects on myeloid differentiation of leukemic cells. Combination treatment with TGFb and ATRA led to growth suppression and monocytic differentiation of HL-60 cells. 260 A similar enhancement of vitamin D3-induced growth arrest and monocytic differentiation of HL-60 and U937 cells was observed following treatment with TGFb. 261, 262 The effects of TGFb on granulocytic differentiation, however, remain ambiguous. Experiments using TGFb antisense oligonucleotides suggest that TGFb promotes ATRA-induced granulocytic differentiation of HL-60 cells. 260 However, other studies have shown that while TGFb augmented the antiproliferative effects of ATRA on HL-60 cells, it had no effect on the granulocytic differentiation of these cells. 263, 264 The differential effect of TGFb on monocytic versus granulocytic differentiation may be explained by the enhancement of Smad2/3 phosphorylation and nuclear translocation during vitamin D3-induced monocytic differentiation, and the reduction of Smad2/3 phosphorylation and nuclear accumulation during ATRA-induced granulocytic differentiation. [265] [266] [267] Conclusions/future perspectives Emerging evidence indicates that multiple signaling pathways are activated during cytokine-induced myeloid differentiation and that these pathways may play critical roles in facilitating the differentiation process. Moreover, the impact that activation of a given pathway has on normal myeloid differentiation may be markedly different from the impact that is seen when that pathway is activated in a differentiation-defective leukemia. Thus, therapeutic inhibition or therapeutic activation of a signaling pathway may have profoundly different consequences for normal versus leukemic cells. A better understanding of the signaling pathways contributing to both normal differentiation and oncogenesis should facilitate the design of more rational therapies.
Current data suggest that cytokine-activated signaling pathways can contribute to myelopoiesis and the myeloid differentiation process via multiple mechanisms. Activated signaling molecules may regulate the expansion of progenitor populations. Knockout models indicate that members of the Src family negatively regulate expansion of the progenitor pool. Alternatively, activated proteins may promote the cell cycle arrest that is necessary for differentiation to occur, as appears to be the case for activated Ras. Other signaling molecules may act primarily to sustain the survival of cells undergoing differentiation, as is likely the case for PI3K and Akt. Still others may act to drive the phenotypic changes associated with the differentiation process. Proteins that exert this biological impact are most likely to be those that directly regulate the expression or activity of key myeloid transcription factors, and include the ERKs, PKC and Ras.
A comprehensive resolution of the roles of different signaling molecules in myeloid differentiation will also need to consider crosstalk between different signaling pathways. Such crosstalk may occur in a stage-specific or lineage-specific manner, and is likely to be complex. In addition, non-proteinaceous regulators of myeloid differentiation should also be investigated. Recent studies have revealed that microRNAs play a role in normal hematopoiesis. 268, 269 The interplay between activated protein signaling pathways and microRNAs during myeloid differentiation should prove to be a fascinating new area of research.
